A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Clinical trial NCT06251973 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06251973
Sponsor: Memorial Sloan Kettering Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Esophageal Carcinoma Advanced Unresectable Gastric Adenocarcinoma Metastatic Gastric Cancer Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Esophageal Cancer Metastatic Esophageal Adenocarcinoma Metastatic Gastric Adenocarcinoma Metastatic Gastric Carcinoma Unresectable Esophageal Cancer Unresectable Esophageal Adenocarcinoma Unresectable Gastric Carcinoma Unresectable Gastric Adenocarcinoma

Start date: 2024-02-01
Primary completion: 2027-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.